Pentraxin 3 promotes oxLDL uptake and inhibits cholesterol efflux from macrophage-derived foam cells

Experimental and Molecular Pathology

Volumn 96, Issue 3, 2014, Pages 292-299

  Liu, Weishuo ^a,b   Jiang, Jianwei ^a   Yan, Dan ^a   Li, Dujuan ^a   Li, Wei ^a   Ma, Yungui ^a   Yang, Lili ^a   Qu, Zhiling ^a   Ruan, Qiurong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Atherosclerosis; Macrophage; Pentraxin 3

Indexed keywords

ATHEROSCLEROSIS; MACROPHAGE; PENTRAXIN 3;

APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; ATP BINDING CASSETTE TRANSPORTER 1; C-REACTIVE PROTEIN; CELL LINE, TUMOR; CHOLESTEROL; CHROMONES; FLAVONOIDS; FOAM CELLS; GENE EXPRESSION; GENE SILENCING; HUMANS; IMIDAZOLES; LIPOPROTEINS, LDL; MITOGEN-ACTIVATED PROTEIN KINASE 3; MORPHOLINES; ORPHAN NUCLEAR RECEPTORS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PPAR GAMMA; PYRIDINES; SERUM AMYLOID P-COMPONENT; SIGNAL TRANSDUCTION;

EID: 84898629186     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2014.03.007     Document Type: Article

References (31)

1. Bottazzi B., Doni A., Garlanda C., Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 2010, 28:157-183.
2. Bujold K., Rhainds D., Jossart C., Febbraio M., Marleau S., Ong H. CD36-mediated cholesterol efflux is associated with PPARγ activation via a MAPK-dependent COX-2 pathway in macrophages. Cardiovasc. Res. 2009, 83:457-464.
3. Choi J.H., Nam K.H., Kim J., Baek M.W., Park J.E., Park H.Y., Kwon H.J., Kwon O.S., Kim D.Y., Oh G.T. Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2404-2409.
4. Duan S.Z., Usher M.G., Mortensen R.M. Peroxisome proliferator-activated receptor-γ-mediated effects in the vasculature. Circ. Res. 2008, 102:283-294.
5. Inoue K., Sugiyama A., Reid P.C., Ito Y., Miyauchi K., Mukai S., Sagara M., Miyamoto K., Satoh H., Kohno I., Kurata T., Ota H., Mantovani A., Hamakubo T., Daida H., Kodama T. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler. Thromb. Vasc. Biol. 2007, 27:161-167.
6. Jing Q., Xin S.M., Zhang W.B., Wang P., Qin Y.W., Pei G. Lysophosphatidylcholine activates p38 and p42/44 mitogen-activated protein kinases in monocytic THP-1 cells, but only p38 activation is involved in its stimulated chemotaxis. Circ. Res. 2000, 87:52-59.
7. Jylhävä J., Haarala A., Kähönen M., Lehtimäki T., Jula A., Moilanen L., Kesäniemi Y.A., Nieminen M.S., Hurme M. Pentraxin 3(PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clin. Exp. Immunol. 2011, 164:211-217.
8. Klingenberg R., Hansson G.K. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur. Heart J. 2009, 30:2838-2844.
9. Klouche M., Peri G., Knabbe C., Eckstein H.H., Schmid F.X., Schmitz G., Mantovani A. Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 2004, 175:221-228.
10. Knoflach M., Kiechl S., Mantovani A., Cuccovillo I., Bottazzi B., Xu Q., Xiao Q., Gasperi A., Mayr A., Kehrer M., Willeit J., Wick G. Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY studies. PLoS One 2012, 7:31474.
11. Latini R., Maggioni A.P., Peri G., Gonzini L., Lucci D., Mocarelli P., Vago L., Pasqualini F., Signorini S., Soldateschi D., Tarli L., Schweiger C., Fresco C., Cecere R., Tognoni G., Mantovani A. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004, 110:2349-2354.
12. Lee G.W., Goodman A.R., Lee T.H., Vilcek J. Relationship of TSG-14 protein to the pentraxin family of major acute-phase proteins. J. Immunol. 1994, 153:3700-3707.
13. Li A.C., Glass C.K. The macrophage foam cell as a target for therapeutic intervention. Nat. Med. 2002, 8:1235-1242.
14. Libby P., Okamoto Y., Rocha V.Z., Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ. J. 2010, 74:213-220.
15. Napoleone E., Di Santo A., Bastone A., Peri G., Mantovani A., de Gaetano G., Donati M.B., Lorenzet R. Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells. A novel link between vascular inflammation and clotting activation. Arterioscler. Thromb. Vasc. Biol. 2002, 22:782-787.
16. Napoleone E., di Santo A., Peri G., Mantovani A., de Gaetano G., Donati M.B., Lorenzet R. The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation. J. Leukoc. Biol. 2004, 76:203-209.
17. Nebuloni M., Pasqualini F., Zerbi P., Lauri E., Mantovani A., Vago L., Garlanda C. PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis. Cardiovasc. Pathol. 2011, 20:27-35.
18. Norata G.D., Marchesi P., Pirillo A., Uboldi P., Chiesa G., Maina V., Garlanda C., Mantovani A., Catapano A.L. Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:925-931.
19. Norata G.D., Marchesi P., Pulakazhi Venu V.K., Pasqualini F., Anselmo A., Moalli F., Pizzitola I., Garlanda C., Mantovani A., Catapano A.L. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009, 120:699-708.
20. Norata G.D., Garlanda C., Catapano A.L. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc. Med. 2010, 20:35-40.
21. O'Connell B.J., Denis M., Genest J. Cellular physiology of cholesterol efflux in vascular endothelial cells. Circulation 2004, 110:2881-2888.
22. Ohashi R., Mu H., Wang X., Yao Q., Chen C. Reverse cholesterol transport and cholesterol efflux in atherosclerosis. Q.J.M. 2005, 98:845-856.
23. Peri G., Introna M., Corradi D., Iacuitti G., Signorini S., Avanzini F., Pizzetti F., Maggioni A.P., Moccetti T., Metra M., Cas L.D., Ghezzi P., Sipe J.D., Re G., Olivetti G., Mantovani A., Latini R. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000, 102:636-641.
24. Rolph M.S., Zimmer S., Bottazzi B., Garlanda C., Mantovani A., Hansson G.K. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 2002, 22:10-14.
25. Rubic T., Lorenz R.L. Downregulated CD36 and oxLDL uptake and stimulated ABCA1/G1 and cholesterol efflux as anti-atherosclerotic mechanisms of interleukin-10. Cardiovasc. Res. 2006, 69:27-535.
26. Savchenko A., Imamura M., Ohashi R., Jiang S., Kawasaki T., Hasegawa G., Emura I., Iwanari H., Sagara M., Tanaka T., Hamakubo T., Kodama T., Naito M. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J. Pathol. 2008, 215:48-55.
27. Steinberg D., Lewis A. Oxidative modification of LDL and atherogenesis. Circulation 1997, 95:1062-1071.
28. Suzuki S., Shishido T., Funayama A., Netsu S., Ishino M., Kitahara T., Sasaki T., Katoh S., Otaki Y., Watanabe T., Shibata Y., Mantovani A., Takeishi Y., Kubota I. Long pentraxin PTX3 exacerbates pressure overload-induced left ventricular dysfunction. PLoS One 2013, 8:e53133.
29. Wang X., Liao D., Bharadwaj U., Li M., Yao Q., Chen C. C-reactive protein inhibits cholesterol efflux from human macrophage-derived foam cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:519-526.
30. Yamaguchi K., Lee S.H., Kim J.S., Wimalasena J., Kitajima S., Baek S.J. Activating transcription factor 3 and early growth response 1 are the novel targets of LY294002 in a phosphatidylinositol 3-kinase-independent pathway. Cancer Res. 2006, 66:2376-2384.
31. Zwaka T.P., Hombach V., Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001, 103:1194-1197.